dc.contributor.author | Sari, R | |
dc.contributor.author | Sevinc, A | |
dc.contributor.author | Buyukberber, S | |
dc.date.accessioned | 2022-03-07T12:50:09Z | |
dc.date.available | 2022-03-07T12:50:09Z | |
dc.date.issued | 2000 | |
dc.identifier.uri | http://hdl.handle.net/11616/54529 | |
dc.description.abstract | Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease. It is rarely associated with severe bone marrow suppression. A case of an elderly woman is reported who developed febrile agranulocytosis two months after commencing ticlopidine but who had a favorable outcome after cessation of that drug and treatment with granulocyte colony-stimulating factor (G-CSF). All patients should have regular monitoring of their blood counts during therapy with ticlopidine. | |
dc.source | ANGIOLOGY | |
dc.title | Ticlopidine-induced severe agranulocytosis after the placement of | |
dc.title | coronary artery stent - A case report |
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |